Pfizer (PFE) Cash & Equivalents (2009 - 2026)

Pfizer (PFE) has reported Cash & Equivalents for 18 consecutive years, with $976.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 40.42% year-over-year to $976.0 million in Q2 2026; TTM through Jun 2026 was $976.0 million, a 40.42% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 9.49% from the prior year.
• Cash & Equivalents was $976.0 million for Q2 2026 at Pfizer, down from $1.7 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $2.9 billion in Q4 2023 and troughed at $416.0 million in Q4 2022.
• A 5-year average of $1.5 billion and a median of $1.4 billion in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 78.6% in 2022 and soared 585.82% in 2023, its largest moves.
• Over 5 years, Cash & Equivalents stood at $416.0 million in 2022, then soared by 585.82% to $2.9 billion in 2023, then tumbled by 63.44% to $1.0 billion in 2024, then increased by 9.49% to $1.1 billion in 2025, then retreated by 14.54% to $976.0 million in 2026.
• The last three Cash & Equivalents figures came in at $976.0 million (Q2 2026), $1.7 billion (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.